Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-EN Version v9-EN
Language English English
Date Updated 2022-05-21 2022-05-21
Drug Identification Number 02387735 02387735
Brand name DYSPORT AESTHETIC DYSPORT AESTHETIC
Common or Proper name abobotulinumtoxinA abobotulinumtoxinA
Company Name IPSEN BIOPHARMACEUTICALS CANADA INC IPSEN BIOPHARMACEUTICALS CANADA INC
Ingredients ABOBOTULINUMTOXINA ABOBOTULINUMTOXINA
Strength(s) 300UNIT 300UNIT
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAMUSCULAR INTRAMUSCULAR INTRAMUSCULAR INTRAMUSCULAR
Packaging size 1 vial 1 vial
ATC code M03AX M03AX
ATC description MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2022-05-04 2022-05-04
Actual start date 2022-05-04 2022-05-04
Estimated end date 2022-05-20 2022-05-20
Actual end date 2022-05-20 2022-05-20
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments Dysport 300u product has seen a significant increase in demand driven by Aesthetic growth. Ipsen are implementing supply capacity improvement projects in order to meet this new growth. During this interim period there will be stock constraints. Dysport 300u product has seen a significant increase in demand driven by Aesthetic growth. Ipsen are implementing supply capacity improvement projects in order to meet this new growth. During this interim period there will be stock constraints.
Health Canada comments